UnitedHealth Group (UNH) Financials

UnitedHealth Group’s latest results show a sharp rebound in profitability in Q1 2026 after a weak finish to 2025, but the balance sheet remains heavily leveraged and liquidity is tied up in a very large liability base.

In Q1 2026, UNH reported $111.7 billion in revenue, up modestly from the prior year’s quarterly range, while net income attributable to common shareholders rose to $6.28 billion, or $6.90 diluted EPS. That was a strong recovery from Q4 2025, when common shareholder earnings were essentially flat at $10 million. Operating income also improved to $9.0 billion from just $0.4 billion in Q4 2025, suggesting the latest quarter benefited from much better operating leverage.

Cash generation also looked solid in Q1 2026. Operating cash flow reached $8.9 billion, well above the prior quarter’s $1.1 billion and ahead of Q1 2025’s $5.5 billion. That is important for a company like UNH because it supports dividends, debt service, and ongoing investment even in a capital-intensive, regulated business.

At the same time, the balance sheet highlights why investors often view UNH as a steady but highly scaled healthcare compounder rather than a low-risk balance-sheet story. Total liabilities stood at $207.3 billion versus total equity of $103.9 billion. Long-term debt was $71.4 billion, and current liabilities of $114.1 billion still exceeded current assets of $91.1 billion, so short-term liquidity depends heavily on continued cash flow generation.

Looking back over the last several years, UNH has shown a clear pattern: revenue growth has been steady, profitability generally strong, and cash flow consistently positive, but leverage and working-capital swings can create quarter-to-quarter noise. The company has also relied on acquisitions over time, which helps expand its scale but leaves a very large goodwill and intangible asset base on the balance sheet.

• Operating income rebounded sharply in Q1 2026 to $9.0 billion from $0.4 billion in Q4 2025.
• Net income attributable to common shareholders improved to $6.28 billion, a major recovery from the prior quarter.
• Operating cash flow was strong at $8.9 billion, giving UNH flexibility to fund dividends, debt, and investments.
• Revenue remained enormous and stable at $111.7 billion in Q1 2026, underscoring the company’s scale.
• Retained earnings were nearly $99.9 billion, showing a long history of cumulative profitability.
• Q4 2025 was a weak quarter with common shareholder earnings near breakeven, so the latest rebound is encouraging but needs follow-through.
• Long-term investments remained sizable at $56.8 billion, providing some financial flexibility.
• Goodwill and intangible assets are very large at $110.5 billion and $20.1 billion, respectively, reflecting acquisition-heavy growth.
• Current liabilities exceeded current assets in Q1 2026, which keeps liquidity pressure on the business.
• Total debt remains high at about $77.9 billion combined short- and long-term debt, leaving UNH sensitive to interest costs and refinancing needs.

Bottom line: UnitedHealth still looks like a highly profitable, cash-generative giant, but investors should watch for two things closely: whether the Q1 2026 earnings rebound is sustainable, and whether leverage plus working-capital demands begin to constrain financial flexibility. For long-term investors, the key question is not whether UNH can generate cash, but whether it can keep converting that scale into steady earnings growth without another profit setback.